CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 enrolled
Drug / intervention
Escitalopram +2 moredrug
Likely dose
Escitalopram 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00296777
NCT00296777Phase 4Completed
CompareCT.gov

Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment

New York State Psychiatric Institute·interventional·Posted Feb 27, 2006·Updated Apr 27, 2012

In Brief

A Phase 4 clinical trial evaluating Escitalopram, Bupropion, and 1 other intervention for Major Depression and Dysthymia. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The main purpose of this study is to correlate brain testing with treatment outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression, Dysthymia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 27, 2006
Enrollment StartDec 1, 2004
Primary CompletionMay 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.3 years ago

Interventions

Escitalopramdrug

8 weeks: up to 40 mg/day

Bupropiondrug

8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.

Imipraminedrug

8 weeks: up to 300mg/day \*if patient does not have contraindication.